These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 33357843)

  • 1. Comprehensive Landscape of Heparin Therapy for COVID-19.
    Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y
    Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.
    Conzelmann C; Müller JA; Perkhofer L; Sparrer KM; Zelikin AN; Münch J; Kleger A
    Clin Med (Lond); 2020 Nov; 20(6):e218-e221. PubMed ID: 32863274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
    Haggag YA; El-Ashmawy NE; Okasha KM
    Med Hypotheses; 2020 Nov; 144():109957. PubMed ID: 32531538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin as a therapy for COVID-19: current evidence and future possibilities.
    Hippensteel JA; LaRiviere WB; Colbert JF; Langouët-Astrié CJ; Schmidt EP
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L211-L217. PubMed ID: 32519894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?
    Giovinazzo G; Gerardi C; Uberti-Foppa C; Lopalco L
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33322757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review on sarilumab in COVID-19.
    Khiali S; Rezagholizadeh A; Entezari-Maleki T
    Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
    [No Abstract]   [Full Text] [Related]  

  • 9. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?
    Rossi GA; Sacco O; Capizzi A; Mastromarino P
    Front Immunol; 2021; 12():670955. PubMed ID: 34093569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
    Xiang J; Lu M; Shi M; Cheng X; Kwakwa KA; Davis JL; Su X; Bakewell SJ; Zhang Y; Fontana F; Xu Y; Veis DJ; DiPersio JF; Ratner L; Sanderson RD; Noseda A; Mollah S; Li J; Weilbaecher KN
    J Virol; 2022 Apr; 96(7):e0005722. PubMed ID: 35319225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from
    Song Y; He P; Rodrigues AL; Datta P; Tandon R; Bates JT; Bierdeman MA; Chen C; Dordick J; Zhang F; Linhardt RJ
    Mar Drugs; 2021 Nov; 19(12):. PubMed ID: 34940684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-anticoagulant heparin derivatives for COVID-19 treatment.
    Cao M; Qiao M; Sohail M; Zhang X
    Int J Biol Macromol; 2023 Jan; 226():974-981. PubMed ID: 36528145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19.
    Zhang BY; Chen M; Chen XC; Cao K; You Y; Qian YJ; Yu WK
    Br J Surg; 2021 Jan; 108(1):e9-e11. PubMed ID: 33640910
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19.
    Chérifi F; Laraba-Djebari F
    Protein J; 2021 Dec; 40(6):799-841. PubMed ID: 34499333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis.
    Dybowska M; Wyrostkiewicz D; Opoka L; Lewandowska K; Sobiecka M; Tomkowski W; Szturmowicz M
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing Antimalarials to Tackle the COVID-19 Pandemic.
    Krishna S; Augustin Y; Wang J; Xu C; Staines HM; Platteeuw H; Kamarulzaman A; Sall A; Kremsner P
    Trends Parasitol; 2021 Jan; 37(1):8-11. PubMed ID: 33153922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.